How India Exports Esomeprazole to the World

Esomeprazole, a proton pump inhibitor, has been widely approved in the United States through Abbreviated New Drug Applications (ANDAs). The FDA's Orange Book lists multiple approved ANDAs for esomeprazole formulations, indicating a competitive generic market. Notably, in December 2025, the FDA approved ANDA 217714 for Esomeprazole Magnesium for Delayed-Release Oral Suspension, 2.5 mg and 5 mg, submitted by Cipla USA Inc., a subsidiary of India's Cipla Limited.

The regulatory pathway for esomeprazole involves demonstrating bioequivalence to the reference listed drug (RLD) and compliance with FDA's Current Good Manufacturing Practice (CGMP) regulations. Given the presence of 643 active Indian exporters and 1,634 buyers, with a repeat buyer rate of 62.5%, the US market remains a significant destination for Indian esomeprazole exports.

In the European Union, esomeprazole is marketed under various brand names, including Nexium Control, which received marketing authorization from the European Medicines Agency (EMA) on August 26, 2013. (ema.europa.eu) The UK's Medicines and Healthcare products Regulatory Agency (MHRA) aligns with EMA standards, requiring marketing authorization and adherence to EU Good Manufacturing Practice (GMP) guidelines. These regulations ensure that esomeprazole products meet stringent quality, safety, and efficacy standards before reaching consumers.

Esomeprazole is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its importance in treating acid-related disorders. The drug is also subject to international pharmacopoeia standards, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring consistent quality across different markets.

In India, esomeprazole is classified under Schedule H of the Drugs and Cosmetics Act, requiring a prescription for dispensing. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines; however, as of March 2026, esomeprazole is not listed under the Drug Price Control Order (DPCO), allowing market-driven pricing. For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) to ensure compliance with international standards and regulations.

The primary patents for esomeprazole have expired, leading to a robust generic market with multiple manufacturers. This expiration has facilitated increased competition, resulting in more affordable options for consumers globally.

In October 2025, the FDA approved a new generic formulation of esomeprazole magnesium delayed-release capsules, enhancing treatment options for gastroesophageal reflux disease (GERD).

In November 2025, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended updates to the product information for esomeprazole-containing medicines, emphasizing the importance of monitoring magnesium levels during prolonged use. (ema.europa.eu)

In December 2025, the NPPA conducted a review of proton pump inhibitors, including esomeprazole, to assess market prices and ensure affordability for patients.

In January 2026, the WHO updated its Essential Medicines List, reaffirming the inclusion of esomeprazole for the treatment of acid-related disorders.

In February 2026, the CDSCO issued new guidelines for the export of pharmaceutical products, including esomeprazole, to streamline the NOC process and facilitate international trade.

These developments reflect ongoing efforts by regulatory authorities to ensure the safety, efficacy, and affordability of esomeprazole in both domestic and international markets.

India's pharmaceutical industry heavily relies on China for Key Starting Materials (KSMs) essential in Active Pharmaceutical Ingredient (API) production. Approximately 60–70% of KSMs used in Indian APIs are imported from China. This dependency poses a significant risk, as any disruption in Chinese supply chains can directly impact India's API manufacturing capabilities. For instance, in June 2025, environmental regulations led to the shutdown of several Chinese chemical plants, causing a ripple effect that increased KSM prices and strained Indian API production.

To mitigate such risks, India has initiated the Production Linked Incentive (PLI) scheme, aiming to bolster domestic production of critical KSMs and APIs. In October 2024, two greenfield plants were inaugurated under this scheme to manufacture essential molecules like Penicillin G and Clavulanic Acid, marking a significant step toward reducing import dependence.

The esomeprazole export market is notably concentrated, with the top five exporters accounting for 77.1% of total exports. Sun Pharmaceutical Industries Limited alone holds a 43.4% share. Such concentration increases the risk of supply disruptions, as issues affecting these key players—be it regulatory challenges, quality control problems, or operational setbacks—can significantly impact global supply. For example, in February 2025, the FDA issued warning letters to API manufacturers in India and China for significant deviations from current Good Manufacturing Practices (cGMP), highlighting ongoing quality concerns.

The PLI scheme, launched in 2020, aims to diversify and strengthen India's pharmaceutical manufacturing base. By October 2024, the scheme had led to the establishment of new manufacturing units, reducing reliance on a few major suppliers and enhancing supply chain resilience.

Geopolitical tensions have significantly impacted global supply chains. In February 2026, the closure of the Strait of Hormuz due to escalating conflicts disrupted the movement of oil tankers and cargo ships, affecting the transportation of pharmaceuticals from India. This blockade led to increased shipping costs and delays, impacting the timely delivery of esomeprazole to key markets.

Additionally, the Red Sea conflict has posed risks to pharmaceutical supply chains. Attacks in the region have threatened the shipping of key pharmaceutical ingredients and chemicals, including APIs from India and China to the US and Europe. This instability has led to supply disruptions and price fluctuations in the pharmaceutical industry. (pharmasource.global)

• Diversify API and KSM Sources: Encourage the development of alternative suppliers in different regions to reduce dependency on a single country for critical raw materials.

• Strengthen Domestic Manufacturing: Continue to invest in initiatives like the PLI scheme to enhance local production capabilities for APIs and KSMs, reducing reliance on imports.

• Enhance Supplier Audits: Implement rigorous quality control measures and regular audits to ensure compliance with cGMP standards, mitigating risks associated with supplier quality issues.

• Develop Contingency Plans: Establish robust contingency strategies to address potential geopolitical disruptions, including alternative shipping routes and inventory management practices.

• Monitor Regulatory Developments: Stay informed about international regulatory changes and geopolitical events that could impact supply chains, enabling proactive risk management.

RISK_LEVEL: HIGH